Crispr Therapeutics Ag (CRSP) Stock Price, Quote & News

Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR...

Industry: Biotechnology

Sector: Healthcare

Phone: 41 41 561 32 77

Website: www.crisprtx.com

Address:

Baarerstrasse 14, Zug, Switzerland

palladium01 Feb. 14 at 5:02 PM

$CRSP enjoy the highway to 75 dollar. in a couple of weeks or months?

0 · Reply

lhes Feb. 14 at 4:09 PM

$CRSP

1 · Reply

DonCorleone77 Feb. 14 at 4:08 PM

$CRSP Crispr Therapeutics price target raised to $76 from $74 at Chardan Chardan analyst Geulah Livshits raised the firm's price target on Crispr Therapeutics to $76 from $74 and keeps a Buy rating on the shares following the Q4 report. The company company is continuing to expand its in vivo cardiovascular editing and siRNA franchises in addition to recent preclinical progress toward in vivo CAR-T capabilities, the analyst tells investors in a research note. Chardan updated Crispr's model post the results.

0 · Reply

george4it Feb. 14 at 3:00 PM

$CRSP I’ll probably be kicking myself for not hanging on that 50 a change buy last week. Oh well on to the next one because I never chase unless I know it’s a sure thing.

1 · Reply

IBott Feb. 14 at 9:07 AM

$CRSP another 6k bought yesterday by ArK!

0 · Reply

Errorplane Feb. 14 at 12:16 AM

$CRSP

0 · Reply

someguytrades Feb. 13 at 10:36 PM

$NTLA $30, $BEAM $150 $CRSP $100 $PRME $1.50

1 · Reply

DragonAlgo Feb. 13 at 9:49 PM

🐉 $CRSP CALL — DragonAlgo® Signal Contract: CRSP CALL Expiry: 2026-02-20 | Strike: $53.00 | Type: CALL Option Plan (premium): Entry: $1.70 Stop: $1.22 TP1: $2.21 TP2: $2.89 TP3: $4.08 🔗 https://dragonalgo.com

0 · Reply

dens214 Feb. 13 at 9:22 PM

$CRSP Started searching for a better managed bootech today. No longer believe crsp can live up to the hype. Corrupted board and poorly managed.

1 · Reply

poorguy Feb. 13 at 8:46 PM

$CRSP It will fall down to $47 range next week!

1 · Reply

CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens

Feb 12, 2026, 4:30 PM EST - 2 days ago

CRISPR Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results

Jan 14, 2026, 11:30 AM EST - 4 weeks ago

Crispr Therapeutics: Patience And Opportunity Through Volatility

Jan 12, 2026, 3:36 PM EST - 4 weeks ago

CRISPR Therapeutics AG (CRSP) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 8:36 AM EST - 4 weeks ago

CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones

Jan 5, 2026, 8:30 AM EST - 5 weeks ago

CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Jan 2, 2026, 12:31 PM EST - 6 weeks ago

Crispr Therapeutics: Prospects For 2026 - Why I Believe Casgevy Is Key

Dec 31, 2025, 5:06 PM EST - 6 weeks ago

Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks

Dec 22, 2025, 12:45 PM EST - 7 weeks ago

CRISPR Therapeutics CRISPR Therapy Shows 90% Response Rate In Aggressive Blood Cancer

Dec 22, 2025, 8:30 AM EST - 7 weeks ago

CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies

Dec 4, 2025, 10:29 AM EST - 2 months ago

Cathie Wood's Buys And Rumors Aside, Here's Why Crispr Therapeutics Is A Strong Buy

Nov 13, 2025, 3:43 PM EST - 3 months ago

CRISPR Therapeutics Post Q3 Earnings: Testing Investor Patience, But Still A Buy

Nov 10, 2025, 8:00 AM EST - 3 months ago

CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Nov 8, 2025, 10:03 AM EST - 3 months ago

CRISPR gene therapy slashes 'bad' cholesterol, triglycerides by half in small study

Nov 8, 2025, 9:56 AM EST - 3 months ago

CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310® Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering

Oct 10, 2025, 8:00 AM EDT - 4 months ago

CRISPR Therapeutics Presents New Preclinical Data for CTX460™ Demonstrating In Vivo Gene Correction of Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase™ Editing Platform

Oct 1, 2025, 8:00 AM EDT - 4 months ago

CRISPR Therapeutics to Present Preclinical Data on Alpha-1 Antitrypsin Deficiency (AATD) Utilizing Novel SyNTase Gene Editing Technology at the European Society of Gene and Cell Therapy (ESGCT) 2025 Annual Congress

Sep 17, 2025, 4:09 PM EDT - 5 months ago

Crispr Therapeutics: Why Stock Fell On Q2 Earnings, And Why We're Now Back On Track

Sep 9, 2025, 4:00 PM EDT - 5 months ago

CRISPR Therapeutics to Present Late-Breaking Data at the American Heart Association (AHA) Scientific Sessions 2025

Sep 9, 2025, 2:22 PM EDT - 5 months ago

Biotech Sector Shows No Signs of Slowing. 3 Stocks That Make the Grade.

INCY XBI XLV

Sep 9, 2025, 11:38 AM EDT - 5 months ago

CRISPR Therapeutics AG (CRSP) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 9, 2025, 6:53 AM EDT - 5 months ago

CRISPR Therapeutics AG (CRSP) Presents at H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 2, 2025, 8:55 AM EDT - 5 months ago

Crispr Therapeutics: A Winning Lottery Ticket Doesn't Replace Grand Strategy

Sep 2, 2025, 8:00 AM EDT - 5 months ago

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Aug 27, 2025, 6:21 AM EDT - 6 months ago

Crispr Therapeutics: A Speculative Buy With Promising Potential Ahead

Aug 14, 2025, 1:02 PM EDT - 6 months ago

Cathie Wood's Top 10 Stock Picks: Unpacking Ark Funds Innovation Picks For The Next Decade

AMD ARKF ARKG ARKK ARKQ ARKW ARKX

Aug 14, 2025, 7:27 AM EDT - 6 months ago

Upgrading Crispr Therapeutics To Hold Ahead Of A Catalyst-Rich 2H 2025

Aug 4, 2025, 4:15 PM EDT - 6 months ago

CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Jul 23, 2025, 11:03 AM EDT - 7 months ago

Crispr Therapeutics: Shares Are Soaring - This Could Be The Start Of Something Big

Jul 15, 2025, 12:01 PM EDT - 7 months ago

The Big 3: ASML, GOOGL, CRSP

ASML GOOG GOOGL

Jul 14, 2025, 8:00 AM EDT - 7 months ago

Crispr Therapeutics' Bright Future Is Coming Into Focus (Rating Upgrade)

Jun 26, 2025, 7:00 AM EDT - 8 months ago

CRISPR Therapeutics Reports Positive Additional Phase 1 Data for CTX310™ Targeting ANGPTL3 and Provides Update on In Vivo Cardiovascular Pipeline

Jun 23, 2025, 12:01 PM EDT - 8 months ago

The Big 3: CRSP, OKLO, GME

OKLO GME

Jun 13, 2025, 6:27 PM EDT - 8 months ago

Crispr Therapeutics: Betting On A One-Shot Future

Jun 9, 2025, 5:50 PM EDT - 8 months ago

CRISPR Therapeutics AG (CRSP) Goldman Sachs 46th Annual Global Healthcare Conference (Transcript)

Jun 3, 2025, 4:07 PM EDT - 9 months ago

CRISPR Therapeutics AG (CRSP) William Blair's 45th Annual Growth Stock Conference (Transcript)

May 9, 2025, 7:14 AM EDT - 10 months ago

Crispr Therapeutics: Complex Casgevy Launch, But Broader Gene-Editing Potential Still Shines

May 8, 2025, 8:36 AM EDT - 10 months ago

CRISPR Therapeutics Struggles Under Slow Adoption And Regulatory Uncertainty (Downgrade)

May 7, 2025, 4:03 PM EDT - 10 months ago

Crispr Therapeutics Q1 Earnings Analysis: Ignore The Gloom, Stay The Course

May 7, 2025, 2:17 PM EDT - 10 months ago

CRISPR Therapeutics' Data Shows Promise, But RFK Jr. Appointee Could Be Negative: Analyst

May 7, 2025, 8:39 AM EDT - 10 months ago

These Analysts Slash Their Forecasts On CRISPR Therapeutics Following Q1 Results

May 6, 2025, 4:01 PM EDT - 10 months ago

CRISPR Therapeutics Provides First Quarter 2025 Financial Results and Announces Positive Top-Line Data from Phase 1 Clinical Trial of CTX310™ Targeting ANGPTL3

May 5, 2025, 4:44 AM EDT - 10 months ago

CRISPR Therapeutics And Intellia Therapeutics: Balancing Market Uncertainty Against Pipeline Catalysts

NTLA

Apr 8, 2025, 3:29 PM EDT - 11 months ago

CRISPR Therapeutics AG (CRSP) Annual Needham Virtual Healthcare Conference (Transcript)

Apr 3, 2025, 8:00 AM EDT - 11 months ago

CRISPR Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 4:01 PM EDT - 11 months ago

CRISPR Therapeutics Announces Transition of Chief Operating Officer

Mar 25, 2025, 11:03 AM EDT - 11 months ago

CRISPR Therapeutics Set To Reach Previous Heights

Mar 3, 2025, 3:28 PM EST - 1 year ago

CRISPR Therapeutics AG (CRSP) TD Cowen 45th Annual Healthcare Conference (Transcript)

Feb 26, 2025, 8:00 AM EST - 1 year ago

CRISPR Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference

Feb 13, 2025, 11:06 AM EST - 1 year ago

Crispr Therapeutics Q4 Earnings Review: Ignore The Lack Of Revenues, Buy The Future

palladium01 Feb. 14 at 5:02 PM

$CRSP enjoy the highway to 75 dollar. in a couple of weeks or months?

0 · Reply

lhes Feb. 14 at 4:09 PM

$CRSP

1 · Reply

DonCorleone77 Feb. 14 at 4:08 PM

0 · Reply

george4it Feb. 14 at 3:00 PM

$CRSP I’ll probably be kicking myself for not hanging on that 50 a change buy last week. Oh well on to the next one because I never chase unless I know it’s a sure thing.

1 · Reply

IBott Feb. 14 at 9:07 AM

$CRSP another 6k bought yesterday by ArK!

0 · Reply

Errorplane Feb. 14 at 12:16 AM

$CRSP

0 · Reply

someguytrades Feb. 13 at 10:36 PM

$NTLA $30, $BEAM $150 $CRSP $100 $PRME $1.50

1 · Reply

DragonAlgo Feb. 13 at 9:49 PM

0 · Reply

dens214 Feb. 13 at 9:22 PM

$CRSP Started searching for a better managed bootech today. No longer believe crsp can live up to the hype. Corrupted board and poorly managed.

1 · Reply

poorguy Feb. 13 at 8:46 PM

$CRSP It will fall down to $47 range next week!

1 · Reply

The_Flying_Janitor Feb. 13 at 8:45 PM

$CRSP opened the app and saw this trending. Glanced at the ticker and the 50% and got pretty excited for half a second 😂 …. My old eyeballs are starting to fail me

2 · Reply

Heap_Of_Funk Feb. 13 at 7:34 PM

$SRPT $SRPT $CRSP you arent listening Short hedge funds are naked shorting and spoofing daily. This scares investors and destroys the share price. Hc Wainwright and his pals like adum fearstun have been destroying investor confidence and the share price. Then you have doug who doesnt do anything about it. Bluebird tragedy in the making. Ceo is stunned

2 · Reply

free2dream Feb. 13 at 7:27 PM

$SRPT how does a micro cap $SRPT pull $400M revenue quarter ? Have the algos been replaced by AI ? On path to have another $2B year if not higher and its valued at $1.8B even effin $CRSP is worth 2x on no sales ?

1 · Reply

IDreambig Feb. 13 at 6:39 PM

$CRSP remember the insider trading few months ago , 50 mil dollars share purchase . All The bears will Try and remind you is a penny trade that sam did . Stupid

0 · Reply